ASH Data Drive Momentum For Revolution In CLL Treatment
Executive Summary
American Society of Hematology meeting provided a platform for J&J/AbbVie’s Imbruvica to continue on its strong upward trajectory and for AbbVie/Roche’s newcomer venetoclax to shine, while Gilead’s flagging Zydelig demonstrated mixed results.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.